Table 3. Validation of Base Case Model Outcomes (Percentage of Patients Alive).

Data Source	Time (mo)
	12	18	24	36	60	120
DBTd
Standard PSM – log logistic	99	98	97	95	89	75
Response-based PSM – exponential (BTd MRD+)	98	97	95	93	88	77
CASSIOPEIA32	98	98	97	—	—	—
BTd
Standard PSM – Weibull	98	97	95	90	81	57
Response-based PSM – exponential (BTd MRD+)	97	94	92	87	78	60
CASSIOPEIA32	98	95	93	—	—	—
GIMEMA36	97	93	91	86	79	60
NHS Digital cohort BTd as first-line treatment (ASCT-positive)37	98	96	93	88	—	—

Abbreviations: ASCT, autologous stem cell transplant; BTd, bortezomib, thalidomide, and dexamethasone; DBTd, daratumumab, bortezomib, thalidomide, and dexamethasone; HR, hazard ratio; MRD+, minimal residual disease–positive; NDMM, newly diagnosed multiple myeloma; PSM, partitioned survival model.